Interim Statement for period ended 30 June 2026

Summary by AI BETAClose X

Clontarf Energy plc reported an interim loss before taxation of £256,000 for the six months ended 30 June 2026, compared to a loss of £245,000 for the same period in 2025, with total assets decreasing to £1,396,000 from £1,940,000 in the prior year. The company's primary focus remains the development of its Bolivian lithium interests using Direct Lithium Extraction technology, with ongoing engagement with Yacimientos de Litio Bolivianos (YLB) and potential financing partners, while also maintaining its oil and gas interests in Ghana. The company's strategy involves advancing pilot-scale testing of NEXT-ChemX's iTDE technology, optimizing lithium and magnesium recoveries, and ultimately deploying commercial-scale DLE facilities, though previously stated deployment schedules are now considered indicative objectives.

Disclaimer*

Clontarf Energy PLC
15 September 2026
 

15 September 2026 

 


Clontarf Energy plc

("Clontarf" or the "Company")

 

Interim Statement for the period ended 30 June 2026

 

Clontarf Energy plc (AIM: CLON), the energy company focused on clean Bolivian Lithium brines, as well as petroleum in Australia and Africa, announces its unaudited financial results for the six months ended 30 June 2026:

 

Overview

 

Our Strategy

·    access to representative bulk brine samples;

·    pilot-scale testing of NEXT-ChemX's ion-Targeting Direct Extraction ("iTDE") technology;

·    technical optimisation of lithium and magnesium recoveries;

·    engagement with Yacimientos de Litio Bolivianos ("YLB");

·    discussions with potential offtakers and financing partners; and

·    ultimately, subject to agreements, permitting, technical verification and financing, deployment of commercial-scale DLE facilities.

 

Bolivia - Political and Commercial Environment

 

YLB

 

Technology & Process

·    high targeted-ion recovery;

·    continuous processing;

·    relatively low energy requirements;

·    reduced fresh-water requirements;

·    modular scalability;

·    reduced reliance on evaporation ponds;

·    recovery of valuable secondary products, particularly magnesium; and

·    the potential production of high-purity lithium compounds.

 

Pilot Testing

·    recovery rates;

·    throughput;

·    membrane performance;

·    operating costs;

·    brine chemistry;

·    magnesium recovery;

·    product purity; and

·    commercial scalability.

 

Commercial Development

 

Funding


 

Ghana


 

New Opportunities

·    lithium and critical/transition minerals;

·    technologies capable of improving extraction economics;

·    suitable opportunities within the Lithium Triangle;

·    selected African critical-mineral opportunities; and

·    oil and gas projects where existing technical knowledge and relationships provide a competitive advantage.

 

Outlook

 

 

 

 

 

James Finn
Interim Chairman
14 September 2026

 

 

 

 

For further information please visit http://clontarfenergy.com or contact:

 

Clontarf Energy

Jim Finn, Director

Peter O'Toole

 

+353 (0) 1 833 2833

Nominated & Financial Adviser

Strand Hanson Limited

Rory Murphy

Ritchie Balmer

+44 (0) 20 7409 3494

Broker

AlbR Capital Limited

Colin Rowbury

+44 (0) 207 399 9400



Public Relations

BlytheRay

Megan Ray

+44 (0) 207 138 3204

 

Teneo

Ciara McNamee

Molly Mooney

 

+353 (1) 661 4055

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 



Six Months Ended

Year Ended

 

30 June 26

30 June 25

31 Dec 25

 

unaudited

unaudited

audited

 

£'000

£'000

£'000

 




Administrative expenses

(169)

(158)

(85)

Impairment of exploration and evaluation assets

(87)

(87)

(174)





LOSS BEFORE TAXATION

(256)

(245)

(259)





Income Tax

                    -

                     -

                      -





COMPREHENSIVE INCOME FOR THE PERIOD

(256)

(245)

(259)





LOSS PER SHARE - basic and diluted

 (0.003p)

 (0.003p)

 (0.003p)













CONDENSED CONSOLIDATED BALANCE SHEET

 30 June 26

 30 June 25

 31 Dec 25

 

 unaudited

 unaudited

 audited

 

 £'000

 £'000

 £'000

ASSETS:

 



NON-CURRENT ASSETS

 



Intangible assets

              260

                434

                347

Investment in Joint Venture

              888

                888

                888


           1,148

             1,322

             1,235





CURRENT ASSETS

 



Other receivables

                    -

                  39

                      -

Cash and cash equivalents

              248

                579

                375

 

              248

                618

                375





TOTAL ASSETS

           1,396

             1,940

             1,610





LIABILITIES:

 



CURRENT LIABILITIES

 



Trade and other liabilities

(1,362)

(1,356)

(1,320)


(1,362)

(1,356)

(1,320)





TOTAL LIABILITIES

(1,362)

(1,356)

(1,320)

NET LIABILITES

                34

                584

                290









EQUITY

 



Called-up share capital

           6,509

             6,509

             6,509

Share premium

         13,517

          13,517

           13,517

Share based payment reserve

              545

                825

                545

Retained deficit

(20,537)

(20,267)

(20,281)

TOTAL EQUITY

                34

                584

                290





 

 

 

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 









 Called-up

 

 Share based

 



 Share

 Share

 Payment

 Retained

 


 Capital

 Premium

 Reserves

 Deficit

 Total

 

 £'000

 £'000

 £'000

 £'000

 £'000

 






As at 1 January 2025

         6,509

       13,517

              825

(20,022)

                829

Total comprehensive income




(245)

(245)

As at 30 June 2025

         6,509

       13,517

              825

(20,267)

                584







Share based payment charge



(280)


(280)

Total comprehensive income



                    -

(14)

(14)

As at 31 December 2025

         6,509

       13,517

              545

(20,281)

                290







Total comprehensive income

                  -

                  -

                    -

(256)

(256)

As at 30 June 2026

         6,509

       13,517

              545

(20,537)

                  34

 

 

CONDENSED CONSOLIDATED CASH FLOW

 Six Months Ended

 Year Ended

 

 30 June 26

 30 June 25

 31 Dec 25

 

 unaudited

 unaudited

 audited

 

 £'000

 £'000

 £'000

CASH FLOW USED IN OPERATING ACTIVITIES

 



Loss for the period

(256)

(245)

(259)

Impairment of exploration and evaluation assets

                87

                  87

                174

Share based payment charge

                    -

                     -

(280)

Exchange movements

                   1

                     -

                     1


(168)

(158)

(364)





Decrease/(increase) in other receivables

                    -

(26)

                  13

Increase/(decrease) in trade and other payables

                42

(55)

(91)

CASH USED BY OPERATIONS

(126)

(239)

(442)





NET CASH USED IN OPERATING ACTIVITIES

(126)

(239)

(442)





CASH FLOWS USED IN INVESTING ACTIVITIES

 



Payments for intangible assets

                    -

                     -

                      -

NET CASH USED IN INVESTING ACTIVITIES

                    -

                     -

                      -





CASH FLOW FROM FINANCING ACTIVITIES

 



Issue of shares

                  -  

                   -  

-

Share issue expenses

                  -  

                   -  

-

NET CASH GENERATED FROM FINANCING ACTIVITIES

-

-

-





NET DECREASE IN CASH AND CASH EQUIVALENTS

(126)

(239)

(442)





Cash and cash equivalents at beginning of the period

              375

                818

                818





Exchange loss on cash and cash equivalents

(1)

                     -

(1)

CASH AND CASH EQUIVALENT AT THE END OF THE PERIOD

              248

                579

                375





 


Notes:

 

1.    INFORMATION

 

The financial information for the six months ended 30 June 2026 and the comparative amounts for the six months ended 30 June 2025 are unaudited. The financial information above does not constitute full statutory accounts within the meaning of section 434 of the Companies Act 2006.

 

The Interim Financial Report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the U.K. The accounting policies and methods of computation used in the preparation of the Interim Financial Report are consistent with those used in the Group 2025 Annual Report, which is available at www.clontarfenergy.com

 

The interim financial statements have not been audited or reviewed by the auditors of the Group pursuant to the Auditing Practices board guidance on Review of Interim Financial Information.

 

 

2.    DIVIDEND

 

No dividend is proposed in respect of the period.

 

 

3.    LOSS PER SHARE

 

Basic loss per share is computed by dividing the loss after taxation for the year attributable to ordinary shareholders by the weighted average number of ordinary shares in issue and ranking for dividend during the year. Diluted earnings per share is computed by dividing the loss after taxation for the year by the weighted average number of ordinary shares in issue, adjusted for the effect of all dilutive potential ordinary shares that were outstanding during the year.

 

 

The following table sets out the computation for basic and diluted earnings per share ("EPS"):

 


Six Months Ended

Year Ended


30 June 26

30 June 25

31 Dec 25

Numerator

£'000

£'000

£'000

Loss for the year

(256)

(245)

(259)





Denominator

Number

Number

Number

For basic and diluted EPS 

8,193,326,117

8,193,326,117

8,193,326,117





(0.003p)

(0.003p)

(0.003p)

 

 

The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of shares for the purposes of the diluted earnings per share

 

 

 


30 June 26

30 June 25

31 Dec 25


Number

Number

Number

 

'000

'000

'000

 

 

 

 

Share options

(615)

(980)

(615)





 

 

 

4.    INTANGIBLE ASSETS


30 June 26

30 June 25

31 Dec 25


£'000

£'000

£'000

Exploration and evaluation assets




Cost:




At 1 January

12,735

12,735

12,735

Additions

-

-

-

Closing Balance

12,735

12,735

12,735

 




Impairment:




At 1 January

12,388

12,214

12,214

Provision for impairment

87

87

174

Closing Balance

12,475

12,301

12,388

 




Carrying value:




At 1 January

347

521

521

At period end

260

434

347

 

 

Exploration and evaluation assets relate to expenditure incurred in prospecting and exploration for lithium, oil and gas in Bolivia and Ghana. The directors are aware that by its nature there is an inherent uncertainty in exploration and evaluation assets and therefore inherent uncertainty in relation to the carrying value of capitalised exploration and evaluation assets.

During 2018 the Group resolved the outstanding issues with the Ghana National Petroleum Company (GNPC) regarding a contract for the development of the Tano 2A Block. The Group has signed a Petroleum Agreement in relation to the block and this agreement awaits ratification by the Ghanian government.

As ratification has not yet been achieved, as a matter of prudence, the directors opted to write down 20% of the carrying value of the Tano 2A Block historic expenditure.  Accordingly, an impairment charge of £173,609 was recorded in the prior and £86,805 in the current period.

The directors believe that there were no facts or circumstances indicating that the carrying value of the remaining intangible assets may exceed their recoverable amount and thus no impairment review was deemed necessary by the directors. The realisation of these intangibles assets is dependent on the successful discovery and development of economic deposit resources and the ability of the Group to raise sufficient finance to develop the projects. It is subject to a number of potential significant risks, as set out below.

 

The Group's activities are subject to a number of significant potential risks including:

 

·        licence obligations;

·        exchange rate risks;

·        uncertainties over development and operational costs;

·        political and legal risks, including agreements with Governments for licences, profit sharing and taxation;

·        foreign investment risks including increases in taxes, royalties and renegotiation of contracts;

·        title to assets;

·        financial risk management;

·        going concern; and

·        ability to raise finance.

 

 

 

 

 

 

5.    INVESTMENT IN JOINT VENTURE

 


30 June 26

30 June 25

31 Dec 25


£'000

£'000

£'000

Cost:




At 1 January

888

888

888

Additions

-

-

-

Closing Balance

888

888

888

Carrying value:




At period end

888

888

888

 

 

 

 

On 15 February 2023 the Group announced a heads of agreement around the potential formation of a 50:50 Joint Venture with US based, OTC Markets traded, technology company, NEXT-ChemX Corporation ("NCX") covering testing, marketing, and deploying of NCX's proprietary (patent pending) ion-Targeting Direct Extraction ("iTDE") technology in Bolivia. Formation of the JV was subject to final due diligence and the parties entering into formal documentation.

The terms of the JV are:

·    A 50:50 joint venture company to be formed on completion of due diligence covering the exclusive rights to the marketing, testing and deployment of the NCX DLE technology in Bolivia.

·    Clontarf Energy plc to contribute $500,000 in cash towards the pilot plant construction and testing as an exclusivity fee for the use of the NCX technology.

·    NCX will then issue shares equal to $500,000 at its next financing (CHMX:OTC) to Clontarf Energy plc. 

·    Clontarf Energy plc will issue shares as follows to NCX:

i.      385 million new Ordinary Shares on proceeding with the Pilot Plant;

ii.     250 million new Ordinary Shares after successful pilot processing of Bolivian brines through the NCX pilot plant; and

iii.    250 million new Ordinary Shares after entry into a construction and processing contract between the JV and the Bolivian authorities on processing of Bolivian brines utilising NCX processing technology.

On 5 May 2023 the Company announced that all conditions had been satisfied with respect to the JV with NCX coming into force. In this regard, Clontarf paid NCX US$500,000 and issued 385 million new Ordinary Shares in the capital of Clontarf of which half was subjected to a 12-month lock in requirement.

The Group's investment in the NEXT‑ChemX joint venture in Bolivia is at an early-stage pre-licence and pre-development phase. As at 30 June 2026, the Group has not yet secured extraction licences or contractual rights to exploit lithium resources in Bolivia, and the joint venture has not commenced commercial operations.

The recoverability of the carrying value of £887,655 is subject to significant uncertainties and is dependent on a number of critical factors, including:

·    successful negotiation and execution of agreements with Yacimientos de Litio Bolivianos (YLB);

·    receipt of bulk brine samples and completion of pilot testing;

·    technical validation and commercial scalability of the direct lithium extraction (DLE) technology;

·    access to funding to progress development stages; and

·    the broader regulatory and political environment in Bolivia.

 

The outcome of the project is inherently binary in nature. If the Group is unable to secure the necessary licences or if pilot testing does not demonstrate commercial viability, the carrying value of the asset may be subject to material impairment, potentially to nil.  Due to the early-stage nature of the project, the Group has not prepared a detailed discounted cash flow model, as there are currently no reliable cash flow projections. Accordingly, the impairment assessment has been performed by reference to the indicators set out in IFRS 6 and management's assessment of the project's prospects.  Management has considered industry benchmarks for the cost of comparable pilot plant developments; however, these benchmarks are used only as an indication of relative cost levels and do not constitute evidence of recoverable value.  The ability to realise value from the investment is also dependent on the Group's capacity to raise sufficient funding to progress the project through development stages.

 

 

      

Deferred Shares - nominal value of 0.24p

 

 

 

Number

 

Share Capital

£'000

Share Premium

£'000

At 1 January 2025

2,370,826,117

5,690

-

At 31 December 2025 and 30 June 2026

2,370,826,117

5,690

-





Ordinary Shares - nominal value of 0.01p



Allotted, called-up and fully paid:

 

 

 

Number

Share Capital

Share Premium

 

 

£'000

£'000

 

 

 

 

At 1 January 2025

8,193,326,117

819

13,517

Issued during the period

-


-

At 30 June 2025

8,193,326,117

819

13,517


 


 

Issued during the period

-

-

-

At 31 December 2025

8,193,326,117

819

13,517





Issued during the period

-

-

-

At 30 June 2026

8,193,326,117

819

13,517

 


 

 

 

There was no movement in the issued share capital in the six months to 30 June 2026.

 

 

 

SHARE OPTIONS

 

The Group issues equity-settled share-based payments to certain Directors and individuals who have performed services for the Group. Equity-settled share-based payments are measured at fair value at the date of grant.

 

Fair value is measured by the use of a Black-Scholes model.

 

 

 

 

 

 

 

 

The Group plan provides for a grant price equal to the average quoted market price of the ordinary shares on the date of grant.

 

 

30 Jun 26

30 Jun 25

31 Dec 25

 

Options Number

'000

Weighted average exercise price in pence

Options Number

'000

Weighted average exercise price in pence

Options Number

'000

Weighted average exercise price in pence

At 1 January

615,500

0.01

980,500

0.035

980,500

0.035

Expired

-

-

-

-

(365,000)

0.045

Outstanding at end of period

615,500

0.01

980,500

0.035

615,500

0.01

Exercisable at end of period

615,500

0.01

980,500

0.035

615,500

0.01

 

There was no movement in the issued share options in the six months to 30 June 2026.

 

 

 

There are no significant post balance sheet events affecting the Company.

 

 

9.   The Interim Report for the six months to 30 June 2026 was approved by the Directors on 14 September 2026.

 

 

10. The Interim Report will be available on the Company's website at www.clontarfenergy.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings